Paper41328347
Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies.
Li Q and 7 others. Theranostics, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies. Papers, record 41328347. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41328347
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genetic Therapy | Major topic |
| Eye Diseases | Major topic |
| Gene Editing | Major topic |
| CRISPR-Cas Systems | Major topic |
| Humans | |
| Animals |
Source PubMed
References192
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33432198 | Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. | Nat Biotechnol | 2021 | https://conductscience.org/library/papers/33432198 | PubMed |
| 2 | 38942756 | PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics. | Nat Commun | 2024 | https://conductscience.org/library/papers/38942756 | PubMed |
| 3 | 19279343 | Primary open-angle glaucoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19279343 | PubMed |
| 4 | 29055361 | The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. | Ophthalmology | 2017 | https://conductscience.org/library/papers/29055361 | PubMed |
| 5 | 26751509 | CRISPR-Cas adaptation: insights into the mechanism of action. | Nat Rev Microbiol | 2016 | https://conductscience.org/library/papers/26751509 | PubMed |
| 6 | 34100716 | Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy. | Elife | 2021 | https://conductscience.org/library/papers/34100716 | PubMed |
| 7 | 30664785 | Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. | Nat Med | 2019 | https://conductscience.org/library/papers/30664785 | PubMed |
| 8 | 24146387 | Glaucoma and the applications of carbonic anhydrase inhibitors. | Subcell Biochem | 2014 | https://conductscience.org/library/papers/24146387 | PubMed |
| 9 | 38466284 | Exploring Heparanase Levels in Tears: Insights From Herpes Simplex Virus-1 Keratitis Patients and Animal Studies. | Invest Ophthalmol Vis Sci | 2024 | https://conductscience.org/library/papers/38466284 | PubMed |
| 10 | 17345604 | Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. | Hum Mutat | 2007 | https://conductscience.org/library/papers/17345604 | PubMed |
| 11 | 26310166 | Introduction to the Retina. | Prog Mol Biol Transl Sci | 2015 | https://conductscience.org/library/papers/26310166 | PubMed |
| 12 | 38582513 | Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38582513 | PubMed |
| 13 | 33152914 | CRISPR/Cas13: A potential therapeutic option of COVID-19. | Biomed Pharmacother | 2020 | https://conductscience.org/library/papers/33152914 | PubMed |
| 14 | 35991315 | Effective splicing restoration of a deep-intronic ABCA4 variant in cone photoreceptor precursor cells by CRISPR/SpCas9 approaches. | Mol Ther Nucleic Acids | 2022 | https://conductscience.org/library/papers/35991315 | PubMed |
| 15 | 32891680 | Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors. | J Control Release | 2020 | https://conductscience.org/library/papers/32891680 | PubMed |
| 16 | 26422227 | Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. | Cell | 2015 | https://conductscience.org/library/papers/26422227 | PubMed |
| 17 | 38518771 | CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38518771 | PubMed |
| 18 | 32157225 | CRISPR treatment inserted directly into the body for first time. | Nature | 2020 | https://conductscience.org/library/papers/32157225 | PubMed |
| 19 | 28392220 | Modeling Developmental and Tumorigenic Aspects of Trilateral Retinoblastoma via Human Embryonic Stem Cells. | Stem Cell Reports | 2017 | https://conductscience.org/library/papers/28392220 | PubMed |
| 20 | 25307992 | Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. | Prog Retin Eye Res | 2015 | https://conductscience.org/library/papers/25307992 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41328347
GET https://conductscience.org/api/papers/v1/41328347/references?page=2